Continuous subcutaneous insulin infusion: its rationale, effectiveness, limitations and role in the treatment of child and adolescent diabetics.
CSII therapy is an attempt to deliver insulin physiologically and to some extent this has been achieved. It is able to reduce blood glucose and HbA1C to normal or near normal level, and correct many other metabolic and functional abnormalities. However, it seems unable to reverse established microangiopathic complications, and may possibly make it worse as in the case of microangiopathy of the retina. Its success depends on the patients' willingness to commit themselves to an intensified programme involving re-education of their knowledge of diabetes, diet and HBGM. Before embarking on CSII therapy, patients should be informed of the other intensified programmes available which give comparable results.